Anders Larsson - Surgical Science CoFounder CTO
| SUS Stock | SEK 151.20 4.30 2.93% |
Insider
Anders Larsson is CoFounder CTO of Surgical Science Sweden
| Age | 50 |
| Phone | 46 3 17 41 65 60 |
| Web | https://www.surgicalscience.com |
Surgical Science Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0357 %, meaning that it generated $0.0357 on every $100 dollars invested by stockholders. Surgical Science's management efficiency ratios could be used to measure how well Surgical Science manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pernilla Linden | Hexatronic Group AB | 54 | |
| Henrik LarssonLyon | Hexatronic Group AB | 57 | |
| Susann Dutt | Hexatronic Group AB | N/A | |
| Lotta Bus | BICO Group AB | 53 | |
| Erica Bell | BICO Group AB | 50 | |
| Tim Ackerman | Swedencare publ AB | N/A | |
| Martin berg | Hexatronic Group AB | 42 | |
| Christian Priess | Hexatronic Group AB | 53 | |
| Fredrik Olsson | Genovis AB | 52 | |
| Matthew Shaw | Swedencare publ AB | 39 | |
| Tomas Jendel | Hexatronic Group AB | 50 | |
| Itedale Redwan | BICO Group AB | N/A | |
| Linda Andersson | Genovis AB | 47 | |
| Hkan Bckstrm | Hexatronic Group AB | 57 | |
| Magnus Eidebo | Hexatronic Group AB | 48 | |
| Jason Clifton | BICO Group AB | N/A | |
| BA BA | Genovis AB | N/A | |
| Hector Martinez | BICO Group AB | 38 | |
| Fredrik Jellberg | MIPS AB | 47 | |
| Maria Edholm | Genovis AB | N/A | |
| Edward Holden | Swedencare publ AB | 42 | |
Management Performance
| Return On Equity | 0.0357 | |||
| Return On Asset | 0.0212 |
Surgical Science Sweden Leadership Team
Elected by the shareholders, the Surgical Science's board of directors comprises two types of representatives: Surgical Science inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surgical. The board's role is to monitor Surgical Science's management team and ensure that shareholders' interests are well served. Surgical Science's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surgical Science's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Inbal MazorBadichi, VP Marketing | ||
| Ran Bronstein, Pres RD | ||
| Anna Ahlberg, Chief Officer | ||
| Adv, Chief Officer | ||
| Daniel Evestedt, Head Devel | ||
| Jeffrey Berkley, Chief Officer | ||
| Martin Jansson, Head Sales | ||
| Anders Larsson, CoFounder CTO | ||
| Gisli Hennermark, Chief Officer | ||
| Doron Zilberman, VP Sales |
Surgical Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Surgical Science a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0357 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 7.68 B | |||
| Shares Outstanding | 50.8 M | |||
| Shares Owned By Insiders | 32.75 % | |||
| Shares Owned By Institutions | 52.03 % | |||
| Price To Book | 1.83 X | |||
| Price To Sales | 10.66 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Surgical Stock Analysis
When running Surgical Science's price analysis, check to measure Surgical Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgical Science is operating at the current time. Most of Surgical Science's value examination focuses on studying past and present price action to predict the probability of Surgical Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgical Science's price. Additionally, you may evaluate how the addition of Surgical Science to your portfolios can decrease your overall portfolio volatility.